| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Section on Pediatric Endocrinology (E.C., T.K., T.I., K.Z., G.P.C.), Reproductive Biology and Medicine Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892; First Department of Pediatrics (G.P.C.), Athens University Medical School, Athens 11527, Greece; and Centro de Endocrinologia (W.J., L.M.), Metabolismo y Diabetes and Clinica, Fundacion Valle del Lili, Cali, Colombia
Address all correspondence and requests for reprints to: Evangelia Charmandari, M.D., Section on Endocrinology and Metabolism, Foundation for Biomedical Research of the Academy of Athens, 4 Soranou Efessiou, Athens 11527, Greece. E-mail: evangelia.charmandari{at}googlemail.com.
Background: Generalized glucocorticoid resistance is a rare condition characterized by partial, end-organ insensitivity to glucocorticoids, compensatory elevations in adrenocorticotropic hormone and cortisol secretion, and increased production of adrenal steroids with androgenic and/or mineralocorticoid activity. We have identified a new case of glucocorticoid resistance caused by a novel mutation of the human glucocorticoid receptor (hGR) gene and studied the molecular mechanisms through which the mutant receptor impairs glucocorticoid signal transduction.
Methods and Results: We identified a novel, single, heterozygous nucleotide (T
C) substitution at position 2209 (exon 9
) of the hGR gene, which resulted in phenylalanine (F) to leucine (L) substitution at amino acid position 737 within helix 11 of the ligand-binding domain of the protein. Compared with the wild-type receptor, the mutant receptor hGR
F737L demonstrated a significant ligand-exposure time-dependent decrease in its ability to transactivate the glucocorticoid-inducible mouse mammary tumor virus promoter in response to dexamethasone and displayed a 2-fold reduction in the affinity for ligand, a 12-fold delay in nuclear translocation, and an abnormal interaction with the glucocorticoid receptor-interacting protein 1 coactivator. The mutant receptor preserved its ability to bind to DNA and exerted a dominant-negative effect on the wild-type hGR
only after a short duration of exposure to the ligand.
Conclusions: The mutant receptor hGR
F737L causes generalized glucocorticoid resistance because of decreased affinity for the ligand, marked delay in nuclear translocation, and/or abnormal interaction with the glucocorticoid receptor-interacting protein 1 coactivator. These findings confirm the importance of the C terminus of the ligand-binding domain of the receptor in conferring transactivational activity.
This article has been cited by other articles:
![]() |
E. Charmandari, T. Ichijo, W. Jubiz, S. Baid, K. Zachman, G. P. Chrousos, and T. Kino A Novel Point Mutation in the Amino Terminal Domain of the Human Glucocorticoid Receptor (hGR) Gene Enhancing hGR-Mediated Gene Expression J. Clin. Endocrinol. Metab., December 1, 2008; 93(12): 4963 - 4968. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Charmandari, T. Kino, T. Ichijo, and G. P. Chrousos Generalized Glucocorticoid Resistance: Clinical Aspects, Molecular Mechanisms, and Implications of a Rare Genetic Disorder J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1563 - 1572. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |